Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351980 | 0.86 | LMNA (0.35) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL21815682 | 0.72 | SIGMAR1 (0.38) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL30292820 | 0.72 | SIGMAR1 (0.38) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL28423984 | 0.70 | SIGMAR1 (0.36) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL21066586 | 0.70 | KEAP1 (0.41) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL1408252 | 0.70 | SIGMAR1 (0.36) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL22028459 | 0.70 | SIGMAR1 (0.36) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL30919258 | 0.70 | SIGMAR1 (0.36) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL30679849 | 0.70 | SIGMAR1 (0.36) | P2RX1P2RX3P2RX4LMNATSHR | |
| SCHEMBL29363156 | 0.70 | SIGMAR1 (0.36) | P2RX1P2RX3P2RX4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701686-B2 | Tricyclopyrazole derivatives | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-11 | — | — | US | disclosed |
| US-20150329552-A1 | TRICYCLOPYRAZOLE DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-11-19 | — | — | US | disclosed |
| US-9127015-B2 | Tricyclopyrazole derivatives | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-09-08 | — | — | US | disclosed |
| EP-2507244-B1 | TRICYCLOPYRAZOLE DERIVATIVES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-11-05 | — | — | EP | disclosed |
| US-20120277214-A1 | TRICYCLOPYRAZOLE DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-01 | — | — | US | disclosed |
| EP-2507244-A1 | TRICYCLOPYRAZOLE DERIVATIVES | Nerviano Medical Sciences S.r.l. (IT) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011067145-A1 | TRICYCLOPYRAZOLE DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329552-A1 | TRICYCLOPYRAZOLE DERIVATIVES | CDK3, MAP3K15, CDK6 | P2RX1 2705/4885P2RX3 2258/4885P2RX4 2317/4885 |
| US-20120277214-A1 | TRICYCLOPYRAZOLE DERIVATIVES | CDK3, MAP3K15, CDK6 | P2RX1 2705/4885P2RX3 2258/4885P2RX4 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.